[A Case of Fanconi Syndrome Induced by Zoledronic Acid in a Metastatic Colorectal Cancer Patient].

Abstract

A 60s-year-old woman with metastatic colorectal cancer was treated using mFOLFOX6 plus bevacizumab. Zoledronic acid was also administered owing to the presence of bone metastasis. The patient was admitted to our hospital with progressive hypokalemia, hypocalcemia, hypophosphatemia, and proximal renal tubular dysfunction. A diagnosis of Fanconi syndrome was made, and was believed to be induced by zoledronic acid treatment. This treatment was discontinued, and the patient's renal tubular function recovered. Denosumab was subsequently administered to treat the bone metastasis, and no renal tubular dysfunction occurred. It was possible to continue chemotherapy, and a complete response was obtained. Fanconi syndrome induced by zoledronic acid is rare, but it may hinder chemotherapy. Therefore, monitoring renal tubular function is recommended during therapy with zoledronic acid.

• Authors: Yutaka Okagawa, Yasushi Sato, Hiroyuki Onuma, Takahiro Osuga, Tsuyoshi Hayashi, Tsutomu Sato, Koji Miyanishi, Masayoshi Kobune, Rishu Takimoto, Junji Kato
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 42 Issue 7 Pg. 867-70 (Jul 2015) ISSN: 0385-0684 [Print] Japan
• PMID: 26197752 (Publication Type: Case Reports, Journal Article)

Chemical References

• Bone Density Conservation Agents
• Diphosphonates
• Imidazoles
• Zoledronic Acid

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bone Density Conservation Agents (adverse effects, therapeutic use)
• Bone Neoplasms (drug therapy, secondary)
• Colorectal Neoplasms (drug therapy, pathology)
• Diphosphonates (adverse effects, therapeutic use)
• Fanconi Syndrome (chemically induced)
• Female
• Humans
• Imidazoles (adverse effects, therapeutic use)
• Positron-Emission Tomography
• Zoledronic Acid